Open Access

Recent advances in the use of resveratrol against Staphylococcus aureus infections (Review)

  • Authors:
    • Wenjing Cui
    • Yadong Wang
    • Li Zhang
    • Fang Liu
    • Guangcai Duan
    • Shuaiyin Chen
    • Jinzhao Long
    • Yuefei Jin
    • Haiyan Yang
  • View Affiliations

  • Published online on: August 30, 2024     https://doi.org/10.3892/mi.2024.191
  • Article Number: 67
  • Copyright : © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

As a notorious bacterial pathogen, Staphylococcus aureus (S. aureus) can readily induce infections in the community and hospital, causing significant morbidity and mortality. With the extensive rise of multiple resistance, conventional antibiotic therapy has rapidly become ineffective for related infections. Resveratrol is a naturally occurring polyphenolic substance that has been demonstrated to have effective antimicrobial activity against S. aureus. Resveratrol at sub‑inhibitory doses can suppress the expression of virulence factors, contributing to attenuated biofilm formation, interference with quorum sensing and the inhibition of the production of toxins. As a promising efflux pump inhibitor, resveratrol enhances antibiotic susceptibility to a certain extent. In conjunction with conventional antibiotics, resveratrol displays unique synergistic effects with norfloxacin and aminoglycoside on S. aureus, yet antagonizes the lethal effects of daptomycin, oxacillin, moxifloxacin and levofloxacin. Nevertheless, given the low oral bioavailability of resveratrol, advanced formulations need to be developed to delay the rapid metabolism conversion to low or inactive conjugates. The present review discusses the antibacterial properties of resveratrol against S. aureus, in an aim to provide in‑depth insight for researchers to address the challenges of antimicrobial resistance.

1. Introduction

Staphylococcus aureus (S. aureus)

a notorious Gram-positive bacterium, is considered one of the causes of high morbidity and mortality worldwide (1). This pathogen belongs to opportunistic bacterial pathogens and normally colonizes in the gastrointestinal tract, anterior nares, axillae and groin in healthy individuals (2,3). The risk of bacterial infections in S. aureus carriers increases when the defense of the host is compromised by physical detriment or other diseases (4). A wide variety of diseases have been related to infections with S. aureus, spanning from minor superficial skin infections to fatal systemic infections, including endocarditis, pneumonia and sepsis (1,5), and S. aureus has been regarded as the primary cause of nosocomial, community-acquired and livestock-acquired infections (6,7). Notably, S. aureus also leads to recurrent infections with the same strains, indicating that previous infections with S. aureus cannot provide protection against subsequent infections (8). Regrettably, due to the extensive and incorrect use of antibiotics, S. aureus has gained marked resistance to several conventional antibiotic classes, causing a rapid emergency of extremely perilous methicillin resistant S. aureus (MRSA) (3). The increasing resistance of this pathogen to diverse conventional antibiotics has posed a major barrier to the therapy of S. aureus infections. Therefore, an effective alternative approach that is not prone to the development of resistance and fewer adverse reactions, may be a new avenue for combating S. aureus infections. Botanical antimicrobials have unique antibacterial properties, and accordingly can be applied to the remedy of S. aureus infections (9-11).

Resveratrol (3,5,4'-trihydroxystilbene), a naturally occurring polyphenolic substance presenting in the stilbene family, can be found in grapes, mulberries, blueberries, cranberries, blackcurrant pomegranates, peanuts, Japanese knotweed, pines, legumes and Theobroma cacao (cacao), and is also found in their relative by-products, including red wine, dark chocolate and juices (12-14). As a bioflavonoid compound, resveratrol is synthesized in response to the stimulation of pathogen attack, ultraviolet irradiation and exposure to ozone (15). Resveratrol possesses two cis and trans forms of isomers, with the latter being the most prevalent in natural forms and particularly abundant in red wine (16). The trans-resveratrol displays several characteristics of higher stability, greater availability and more biological activity (17). Recently, this compound has gained increasing attention for its pharmacological and beneficial functions, including anticancer, anti-inflammatory, anti-obesity, antidiabetic, antiaging, and neuroprotective, antiangiogenic, immunoregulatory, cardioprotective and antioxidant activity (18,19). Furthermore, resveratrol is also known to exhibit antibacterial, antiviral and antifungal activity (20). Recently, a number of studies have explored the antibacterial efficacy, mechanisms and the combined effect of resveratrol against S. aureus (2,21). To the best of our knowledge, to date, a comprehensive review on this topic has not been published. Thus, the present study comprehensively reviewed the reported antibacterial activity of resveratrol against S. aureus, as well as the opportunities and limitations of developing resveratrol into an effective antibacterial agent.

2. Antibacterial activity of resveratrol against S. aureus

Resveratrol has been widely investigated for its capacity to suppress the growth of S. aureus, with its antibacterial activity being assessed by the minimal inhibitory concentration (MIC). The information reported about resveratrol against various species of S. aureus is summarized in Table I. Resveratrol exhibits growth inhibitory activity at concentrations of approximately >100 µg/ml against S. aureus. The data from the literature have revealed marked variations in the MIC values, depending on the strains of S. aureus. Furthermore, resveratrol has also been shown to exhibit relatively moderate antimicrobial activity against S. aureus strains, such as ATCC 25923 (22-24), COL (25), MTCC 737(26), RN 450(27), SA 1199(2), SA 1199B (2), SAK 1758(2), ATCC 33591(24), 8325-4(28), N315(29) and ATCC 29213(30) with MIC values of ~100-200 µg/ml. Other studies have revealed that resveratrol exerts weak antibacterial activity against S. aureus strains with MICs ≥256 µg/ml (2,21,25,31-38).

Table I

Summary of the antimicrobial properties of resveratrol against S. aureus.

Table I

Summary of the antimicrobial properties of resveratrol against S. aureus.

IdentifierMIC (µg/ml)Cultivation mediumTest method(Refs.)
ATCC 25923100MHBBroth microdilution method(23)
ATCC 25923>1,000LB brothBroth microdilution method(31)
ATCC 25923256MHBBroth microdilution method(32)
ATCC 25923312.5MHBBroth microdilution method(33)
ATCC 25923200MHBBroth microdilution method(24)
ATCC 25923200TSBBroth microdilution method(22)
ATCC 33592256MHBBroth microdilution method(32)
JE2256TSBBroth microdilution method(25)
COL128TSBBroth microdilution method(25)
USA 300256TSBBroth microdilution method(38)
Newman512TSBBroth microdilution method(25)
MTCC 737100MHBBroth microdilution method(26)
RN 450150MHBBroth microdilution method(27)
SA 1199200MHBBroth microdilution method(2)
SA 1199B100MHBBroth microdilution method(2)
NCTC 8325-4400MHBBroth microdilution method(2)
SAK 1758200MHBBroth microdilution method(2)
ATCC 33591100MHBBroth microdilution method(24)
Clinical isolate350TSBBroth microdilution method(34)
Clinical isolate500BHIBroth microdilution method(21)
ATCC 33591>512MHBBroth microdilution method(32)
ATCC 29213>512MHBBroth microdilution method(32)
ATCC BAA976>512MHBBroth microdilution method(32)
ATCC 43300>512MHBBroth microdilution method(32)
Two clinical isolates>512MHBBroth microdilution method(32)
8325-4125MHBBroth microdilution method(28)
ATCC 433001,000MHAAgar dilution method(35)
ATCC 292131,000MHAAgar dilution method(35)
ATCC 29213171MHBBroth microdilution method(30)
Clinical isolates250-1,000MHAAgar dilution method(35)
N315>100NAaBroth microdilution method(29)
Clinical isolates512TSBBroth microdilution method(36)
CECT 59>2,000TSB-YENA(37)

[i] SAK 1199B is a norA-overexpressing strain, and its wild-type S. aureus strain is SA 1199. Strain SAK 1758 is a norA deletion mutant of NCTC 8325-4. S. aureus, Staphylococcus aureus; MIC, minimum inhibitory concentration; TSB, tryptic soy broth; BHI, brain heart infusion broth; MHA, Mueller-Hinton agar; LB, Luria-Bertani broth; MHB, Mueller-Hinton broth; TSB-YE, tryptic soy broth containing 0.6% (w/v) yeast extract; NA, not available.

Nevertheless, the reported MIC values of the same strain exhibit noticeable disparities. For instance, resveratrol has been shown to exhibit antimicrobial activity with an MIC value of >1,000 µg/ml (31) for S. aureus ATCC 25923, whereas other studies have indicated that the MIC values were 100 µg/ml (23), 256 µg/ml (32), 312.5 µg/ml (33) and 200 µg/ml (22,24). The reason for this variance is likely attributed to differences in culture conditions, with growth mediums of Luria-Bertani (LB) broth, Mueller-Hinton broth (MHB), MHB, MHB, and tryptic soy broth (TSB), respectively. Similarly, there are notable differences in MIC values for the same strain ATCC 29213 due to the discrepancy in the test method, with an MIC value of 1,000 µg/ml determined on the agar method (35), while the study by Chan (30) demonstrated an MIC value of 171 µg/ml measured by the broth test. In summary, the reason for this variance is likely attributed to the following: i) Strain variance; ii) differences in growth conditions (i.e., LB broth vs. MHB vs. TSB); iii) the discrepancy in the test method (broth microdilution method vs. agar dilution method).

Additionally, the bacteriostatic and bactericidal effects of resveratrol could be detected using time-kill curves. Resveratrol has been shown to exert a bacteriostatic effect against S. aureus at concentrations equivalent to 1-3 x MIC compared with the untreated control (23,25). By contrast, resveratrol as a standalone component fails to exert a bactericidal effect against S. aureus. At sub-inhibitory concentrations (0.5 x MIC), resveratrol presents bactericidal activity synergized with gentamicin against S. aureus (25).

Taken together, resveratrol exerts a bacteriostatic effect against S. aureus with MICs ranging from 100 to >1,000 µg/ml. Further investigations are expected to provide additional information on the varying susceptibility of resveratrol to different strains of S. aureus, which is of utmost importance for the development of antibacterial drugs.

3. Anti-virulence properties against S. aureus

Given the alarming global spread of antibiotic resistance and the limitation of optional functional antibiotics, the virulence mechanism of S. aureus has attracted the attention of numerous scientists (1). S. aureus releases a wide range of virulence factors to cause diseases and evade host defenses in the host (39), and promotes the change from colonization to systemic infection (40). S. aureus infection depends on the secretion of toxins that cause damage to host cells and tissues, and is also dependent on the production of a plethora of protein and non-protein factors to facilitate the establishment of infection that initiate bacterial adhesion, invasion, colonization and biofilm production (41). Virulence is subject to strict regulation in response to bacterial requirements in a coordinated manner to decrease unnecessary metabolic demands (3,42). Nevertheless, resveratrol presents the ability to alleviate the virulence induced by S. aureus by preventing the production of biofilm, interfering with quorum sensing (QS) and inhibiting the release of toxins. The anti-virulence mechanism of resveratrol against S. aureus is illustrated in Fig. 1.

Anti-biofilm properties

Biofilms consist of microbial community structure adhered to a surface and encased in an extracellular polymeric matrix (43). The biofilm establishment provides a protective atmosphere for S. aureus, helping the bacteria escape host or antimicrobial defense (41), which is responsible for the emergence of antibiotic resistance, and contributes to various chronic and persistent infections (44). Therefore, anti-biofilm is an important strategy against chronic and persistent infections caused by S. aureus.

Resveratrol has been reported for its capacity to suppress biofilm formation against S. aureus (34,45). In a previous study, the biofilm was reduced by ~38% under the induction of resveratrol, as compared with the untreated control group (24). Resveratrol has been revealed to have antibiofilm properties at concentrations 3-4-fold lower than the MIC values, and in conjunction with vancomycin, it exhibits a more potent activity against established biofilm by disrupting the expression of genes linked to surface and secreted proteins, capsular polysaccharide and QS (34). Notably, it has also been revealed that resveratrol, at extremely low concentrations (5 µg/ml), increases the biofilm formation of S. aureus, although the biofilm is diminished with the increasing concentrations of resveratrol. The observed augmentation of biofilm formation at low resveratrol concentrations may be attributed to the cellular stress response triggered by the antimicrobial agents (46). By contrast, resveratrol has been shown to exert no significant inhibitory effects on biofilm formation by S. aureus in some other studies (26,47,48), suggesting that the testing conditions and the strain type may have an impact on the various biofilm inhibitory effects.

Interference with QS

The quorum sensing (QS) system conduces to cell-to-cell communication, allowing bacteria to modify their behaviors in response to the fluctuations in cell density (49,50). QS participates in the generation and release of extracellular signal molecules termed autoinducing peptides (AIPs) which regulate virulence gene expression with a reached threshold concentration of AIPs (49). A broad range of bacteria, including S. aureus utilize the QS system to regulate significant bacterial behaviors, such as biofilm establishment, attachment to surfaces, virulence and pathogenicity (51). The accessory gene regulator (agr) locus, composed of two different transcriptional units triggered by P2 and P3 promoters, serves as an important regulator and controls the expression of virulence factors in the S. aureus QS system (52,53). The P3 operon is related to the expression of RNAⅢ, which has been proven to have implications for the activation of a series of secreted virulence proteins (54). The P2 operon transcribes RNAⅡ, which is involved in the synthesis of AgrA, AgrB, AgrC and AgrD (54).

Resveratrol has been observed for its capacity to interfere with the QS activity of S. aureus (34). Through its interaction with AgrA and AgrC proteins, resveratrol inhibits the QS signal transmission of S. aureus (34,51). As shown in a previous study, following treatment with resveratrol, the transcriptional levels of the effector molecule RNAIII in the agr system decreased by 3.5-fold in contrast to the untreated group (38). The hld gene located in RNAIII encodes the δ-toxin (55). A previous study indicated that resveratrol downregulated the expression of the hld gene (36), whereas another study revealed that resveratrol upregulated the expression of hld in the QS system (34). Thus, the effects of resveratrol on the expression of the hld gene in S. aureus warrant further investigations.

Inhibition of toxins of S. aureus

Toxins are one of the various factors possessed by S. aureus that play a crucial role in the development and progression of diseases. However, research has demonstrated that resveratrol exerts inhibitory effects on the levels of toxins of S. aureus. It has been demonstrated that the supplementation of resveratrol (at a sub-inhibitory concentration of 50 µg/ml) downregulates the levels of the enterotoxin genes sea and seb, and inhibits the expression of the leucocidin lukF and lukS genes (21).

Notably, alpha-hemolysin (Hla), a potent pore-forming toxin generated by S. aureus, plays a crucial role in the emergence of severe symptoms caused by S. aureus (36). Following binding to the membrane of a target receptor, pore formation on cell membranes triggers the disruption of homeostasis, leading to a variety of cell damage and death (56). Hla-deficient mutants exhibit markedly decreased pathogenicity in various infected animal models (57). Hence, targeting hemolysin for drug development may provide an ideal approach for the development of anti-virulence therapies for S. aureus infections. It has been shown that resveratrol significantly attenuates the hemolytic capacity of S. aureus in a dose-dependent manner, especially at 1/8 MIC, although no discernible impact on bacterial growth was observed (38). The mechanism of regulation by resveratrol has been elucidated, encompassing the downregulation of the transcription of the hla gene which encodes Hla, as well as the reduction of RNAIII transcription within the agr system (38). The study by Duan et al (36) reported that resveratrol at sub-inhibitory doses reduced the levels of hla and saeRS in S. aureus strains. Treatment with resveratrol significantly decreased the hemolysis of rabbit erythrocytes infected by S. aureus in a dose-dependent manner in the hemolysis assay. Resveratrol was also found to lower the synthesis of Hla, thereby reducing the hemolytic competence (36).

Furthermore, it has been reported that bacterial proteases are also responsible for the virulence development of S. aureus. The immune response of the host is disrupted by bacterial proteases by interacting with antimicrobial peptides, plasma proteins and neutrophils. Additionally, proteases can shield pathogens from damage by compromising the integrity of the extracellular matrix (58). At sub-inhibitory concentrations, resveratrol significantly reduces the production of protease and lecithinase of S. aureus (59). These findings provide additional proof of the potential of resveratrol as a promising treatment strategy against S. aureus infections.

4. Resveratrol as an efflux pump inhibitor

Microbial efflux pumps are known to be involved in the development of multidrug resistance by extruding antibiotics to the extracellular medium, resulting in the intrinsic and acquired resistance of bacteria (60). Moreover, the efflux pump system has also been considered to participate in the regulation of virulence factors in S. aureus (61). Among the different efflux pump families, the major facilitator superfamily plays a dominant role in Gram-positive bacteria, for which the NorA efflux pump has been widely studied and is an interesting target in S. aureus (60,62). In view of the fact that the emergence of antibiotic resistance is closely linked to the activation of the efflux pump, the establishment of efflux pump inhibitors (EPIs) may prove to be a promising treatment strategy for the identification of therapeutic targets of drug-resistant S. aureus strains, along with seeking out drug adjuvant to increase antibiotic sensitivity.

Resveratrol has been investigated on a variety of bacteria, including S. aureus for its capacity to inhibit the efflux pump by augmenting the intracellular accumulation of antimicrobials. As previously demonstrated, the MIC of norfloxacin against S. aureus SA1199B (NorA-overexpressing strain) decreased by 16-fold in the presence of resveratrol (2). Additionally, it was demonstrated that in the presence of resveratrol, the SA1199B strain had augmented fluorescence due to the accumulation of ethidium bromide. These results suggest that resveratrol inhibits NorA (2), indicating the possibility of functioning as an EPI.

In addition to the aforementioned mechanisms, the three S. aureus JE2 mutants with electron transport chain defect (menD, hemB and aroC) exhibit an increased sensitivity to resveratrol, indicating that resveratrol exerts an antibacterial effect by disrupting the energy metabolism in S. aureus. Resveratrol at sub-inhibitory concentrations interferes with the DNA integrity of S. aureus, while upregulating the expression of the SOS-stress response genes, lexA and recA. It has been revealed that these DNA repair systems are essential in assisting the defense of S. aureus against the inhibitory effects of resveratrol (63). Moreover, resveratrol, as an ATP synthase inhibitor, has been shown to sensitize S. aureus to naturally existing antimicrobial peptides of the innate immune system, particularly to hBD4-mediated killing (64). Future research is required however, to explore more potential mechanisms of resveratrol against S. aureus as an assistance to develop novel antibacterial therapies.

5. Resveratrol in combination with conventional antimicrobials

Apart from exhibiting antimicrobial efficacy as a standalone compound, resveratrol has additionally been found to be involved in potential interactions either antagonistic or synergistic effects in combination with commonly utilized antimicrobials (Table II and Fig. 2). Notably, it has been shown that resveratrol (0.25 x MIC) substantially enhances the efficacy of norfloxacin against S. aureus and to a greater degree in the type of norA-overexpressing strain in S. aureus (16-fold increase) (2). It has been found that one potential mechanism for potentiating the potency of this antibiotic against S. aureus may involve the suppression of the NorA efflux pump (2). Furthermore, it has been demonstrated resveratrol at a concentration equal to 0.5 MIC (128 µg/ml) augments the bactericidal activity of aminoglycosides by ~32-fold against S. aureus through ATP synthase suppression (25). In addition, the inactivation of the gene encoding ATP synthase by resveratrol also promotes the increased susceptibility of S. aureus towards aminoglycosides (25,63), polymyxins (65,66) and certain human antimicrobial peptides (64). Of note, potential protection from antibiotic-induced adverse effects has been observed following co-treatment with resveratrol (67).

Table II

Effects of resveratrol combined with different types of antibiotics against S. aureus strains.

Table II

Effects of resveratrol combined with different types of antibiotics against S. aureus strains.

 MIC (µg/ml)a 
Bacterial strainsAntibiotics(-) RE(+) RERE concentrationFold changebEffect(Refs.)
SA1199BNorfloxacinNANA0.25 x MIC (25 µg/ml)16 ↓Synergistic(2)
SA1199NorfloxacinNANA0.25 x MIC (50 µg/ml)NA ↓Synergistic(2)
NCTC 8325-4NorfloxacinNANA0.25 x MIC (100 µg/ml)NA ↓Synergistic(2)
JE2Gentamicin10.063-0.1250.5 x MIC (128 µg/ml)8-16 ↓Synergistic(25)
COLGentamicin0.250.0310.5 x MIC (64 µg/ml)8 ↓Synergistic(25)
NewmanGentamicin10.063-0.250.5 x MIC (256 µg/ml)4-16 ↓Synergistic(25)
JE2Kanamycin80.50.5 x MIC (128 µg/ml)16 ↓Synergistic(25)
JE2Tobramycin20.0630.5 x MIC (128 µg/ml)32 ↓Synergistic(25)
JE2Neomycin40.125-0.250.5 x MIC (128 µg/ml)16-32 ↓Synergistic(25)
JE2Streptomycin16-3220.5 x MIC (128 µg/ml)8-16 ↓Synergistic(25)
RN450Ciprofloxacin0.50.250.5 x MIC (75 µg/ml)2 ↑Antagonistic(27)
RN450Moxifloxacin0.060.060.5 x MIC (75 µg/ml)-Antagonistic(27)
RN450Oxacillin0.250.250.5 x MIC (75 µg/ml)-Antagonistic(27)
RN450Daptomycin0.060.060.5 x MIC (75 µg/ml)-Antagonistic(27)
ATCC 25923Levofloxacin-cNA15 µg/ml-Antagonistic(68)

[i] aMinimum inhibitory concentration of antibiotics (with or without resveratrol) against S. aureus.

[ii] bFold change: ↓ indicates fold reduction; ↑ indicates fold increase; - indicates no fold change.

[iii] cLevofloxacin treatment (1-128 MIC, MIC=0.125 µg/ml). S. aureus, Staphylococcus aureus; MIC, minimum inhibitory concentration; NA, not available; RE, resveratrol.

By contrast, it has been reported that resveratrol increases the survival of S. aureus when subjected to treatment with partially bactericidal antibiotics. It has been revealed that resveratrol at a concentration of 15 µg/ml, which is ineffective in inhibiting the growth of bacteria, combined with levofloxacin at the range of 1-128 MIC significantly increases the survivability of S. aureus compared with the antibiotic alone. Notably, the bactericidal effect generated by levofloxacin (8 x MIC) combined with resveratrol has been found to be comparable to that of levofloxacin alone at 1 MIC (68). In addition, another study demonstrated that resveratrol at sub-inhibitory concentrations equivalent to 0.5 MIC (75 µg/ml) considerably counteracted the bactericidal effects of moxifloxacin, daptomycin and oxacillin (27). The protective mechanism was revealed to be associated with the inhibition of the accumulation of reactive oxygen species (ROS) exerted by resveratrol (68). ROS have been suggested to be produced during the process of antimicrobial therapy, conducing to the rapid bacterial killing effect of antimicrobial agents (69). Resveratrol, as a scavenger of ROS, may shield cells from damage induced by ROS, although it interferes with the bactericidal action of the aforementioned antibiotics, reducing the death of S. aureus (68). It has been revealed that ROS exert a lethal, as opposed to a bacteriostatic effect on antibiotics; thus, resveratrol exerts minimal effects on antibiotic MICs (27). Furthermore, previous research has shown that resveratrol possesses the capacity to facilitate the mutant recovery, which may potentially result in the development of antibiotic resistance (27). Conversely, another study demonstrated the capacity of resveratrol to effectively suppress the mutation frequency of norfloxacin against S. aureus (2).

Taken together, resveratrol modifies the activity of various types of conventional antibiotics, suggesting that the consumption of resveratrol should be rigorously monitored during antibacterial treatment. Additionally, it remains to be determined whether the aforementioned findings are also applicable to animal models.

6. In vivo antimicrobial activity of resveratrol

Several studies have extensively documented the significant therapeutic effects of resveratrol in animal models against S. aureus infections (36,38,70-74). In previous studies on mouse models of pneumonia caused by S. aureus, the subcutaneous administration of resveratrol significantly ameliorated S. aureus-induced pneumonia (38,74) by reducing the NLRP3-mediated inflammation (74). In a previous study, the intraperitoneal administration of resveratrol diminished the expression of vascular cell adhesion molecule-1 (VCAM-1) triggered by heat-killed S. aureus in the lungs of mice, decreased the leucocyte count of the bronchoalveolar lavage fluid in mice, and inhibited pulmonary -hematoma caused by heat-killed S. aureus (72). In a murine model of purulent infections, the transdermal absorption of resveratrol promoted the elimination of S. aureus from wounds by inhibiting the infiltration of mast cells and stimulating the infiltration of both lymphocytes and macrophages into the wound (73). Another study demonstrated that the subcutaneous injection of resveratrol at sub-inhibitory concentrations reduced abscess sizes in a mouse model of skin infections induced by S. aureus, suggesting that resveratrol could certainly mitigate the virulence of S. aureus (36). For the MRSA intradermal infection model in mice, photoactivated resveratrol was observed to augment the myeloperoxidase expression, diminish the bacterial load and control inflammation through the production of IL-10 in the draining lymph node (70). Photoactivated resveratrol was also reported to display an increase in antibacterial activity against MRSA infections in mice, which could potentially be attributed to the singlet oxygen formation; resveratrol was also shown to have an impact on the immune system that involved inducing the production of IL-17 and TNF-α (71).

However, resveratrol has exhibited high absorption in humans, but limited oral bioavailability, which restricts its therapeutic application as an effective antibacterial agent (75). Following oral administration, resveratrol exhibits an oral bioavailability of <1% due to its rapid conversion in the liver and gut to less active glucuronides and sulfates (75,76). It was previously shown that the peak levels of metabolites reached 3- to 8-fold greater than the plasma concentrations of unaltered resveratrol (77). It was demonstrated that the oral administration of a single dosage of 5 g resveratrol led to peak plasma levels of up to 539 ng/ml after 1.5 h (77). Similarly, in another study, the unaltered resveratrol in the plasma was almost undetectable even after repeatedly administering high doses of 5 g for 28 days (78). The bioavailability of resveratrol appears not to change in response to dose escalation and repeated dose administration (76). Given the poor bioavailability, this route of oral administration of resveratrol in the remedy of bacterial infections may not be sufficient to reach the suppressive concentrations required for therapy. Due to the rapid transformation of resveratrol in humans, there exist high plasma concentrations of resveratrol metabolites. The activity of the resveratrol conjugates has been shown to be incredibly weak in in vitro studies in comparison with the original compound (79); however, the activity remains unknown in vivo. Additionally, rapid metabolism has still been observed following the intravenous administration of resveratrol, revealing that rapid sulfate conjugation by the intestine and liver appears to be the speed-limiting step in the bioavailability of resveratrol (80). Furthermore, the topical application of resveratrol may prove effective for reducing the conjugation and metabolism in preventing related infectious diseases (81).

Taken together, further studies are required to focus on improving the oral bioavailability and exploring topical application for the treatment of skin disease caused by S. aureus, even in conjunction with traditional antibiotics.

7. Safety and tolerance associated with the use of resveratrol in humans

Although resveratrol is generally regarded as safe and well-tolerated in humans, occasional adverse effects still exist (82). The most common reported symptoms are gastrointestinal side-effects; other side-effects include nephrotoxicity, hypersensitivity, weight loss, pruritus and frontal headache (17,83-85). Individuals taking high doses of resveratrol (2-5 g per day) and those with pathological conditions are prone to suffer from adverse reactions (84). A previous systematic review on the supplementation of resveratrol in older adults with chronic diseases revealed an excellent safety profile. Nevertheless, some biomarkers of cardiovascular disease risk increase at high doses in overweight individuals (86). Furthermore, a long-term 52-week course of resveratrol treatment (with a dose of 500 mg/day and escalated every 13 weeks to a maximum dose of 1,000 mg/day over a period of 53 weeks) revealed that it was safe and well-tolerated, although adverse effects, including nausea and diarrhea were observed (83).

Taken together, resveratrol appears to be safe and well-tolerated. However, further research is required in order to determine the safety and long-term effects of high doses of resveratrol supplementation in humans, particularly when evaluating the co-administration of resveratrol with other pharmaceuticals.

8. Conclusions and future perspectives

With the emergence of antibiotic resistance, the beneficial effects and therapeutic values of resveratrol have drawn an abundance of attention from scientists. In the present review, resveratrol was reported to display antimicrobial activity at concentrations of >100 µg/ml against S. aureus, and the antimicrobial effect on S. aureus is bacteriostatic rather than bactericidal. Resveratrol also exhibits anti-virulence properties by suppressing biofilm formation, interfering with the expression of QS system, and suppressing the generation of toxins.

In addition, the potential interactions with different types of conventional antimicrobials should be considered in its applications. Resveratrol augments the efficacy of norfloxacin, as well as aminoglycosides, whereas it lowers the bactericidal lethal activity of levofloxacin, daptomycin, moxifloxacin and oxacillin against S. aureus. Therefore, future studies are warranted to discern the role of resveratrol as a potentiator or antagonist in conjunction with other treatments. Furthermore, it is noteworthy that the concentration of resveratrol following oral administration that exerted antimicrobial properties is greater than that in plasma, as a result of the limited bioavailability and rapid metabolism of resveratrol, which restricts the treatment of infections by oral administration. Moreover, the oral administration of a large amount of resveratrol may increase the risk of unfavorable events. Therefore, for the purpose of improving the bioavailability of resveratrol, it is necessary to develop more sophisticated oral preparations to postpone or prevent rapid metabolism to less activity in the liver and intestine. Other ongoing studies have been carried out to improve the bioavailability of resveratrol, such as nano-delivery systems (85), and future studies are required to focus on the evaluation of various formulations in humans.

Acknowledgements

Not applicable.

Funding

Funding: The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 82273696 and 81973105).

Availability of data and materials

Not applicable.

Authors' contributions

GD and HY conceptualized the study. WC, YW, LZ, FL, YJ, JL and SC performed the literature search, designed the study and prepared the figures. WC wrote the manuscript. All the authors have reviewed and modified the final manuscript, and all authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Cheung GYC, Bae JS and Otto M: Pathogenicity and virulence of Staphylococcus aureus. Virulence. 12:547–569. 2021.PubMed/NCBI View Article : Google Scholar

2 

Santos M, Santos R, Soeiro P, Silvestre S and Ferreira S: Resveratrol as an inhibitor of the NorA efflux pump and resistance modulator in Staphylococcus aureus. Antibiotics (Basel). 12(1168)2023.PubMed/NCBI View Article : Google Scholar

3 

Shoaib M, Aqib AI, Muzammil I, Majeed N, Bhutta ZA, Kulyar MFEA, Fatima M, Zaheer CF, Muneer A, Murtaza M, et al: MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework. Front Microbiol. 13(1067284)2023.PubMed/NCBI View Article : Google Scholar

4 

Wertheim HFL, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA and Nouwen JL: The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 5:751–762. 2005.PubMed/NCBI View Article : Google Scholar

5 

David MZ and Daum RS: Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 23:616–687. 2010.PubMed/NCBI View Article : Google Scholar

6 

Wang Y, Zhang P, Wu J, Chen S, Jin Y, Long J, Duan G and Yang H: Transmission of livestock-associated methicillin-resistant Staphylococcus aureus between animals, environment, and humans in the farm. Environ Sci Pollut Res Int. 30:86521–86539. 2023.PubMed/NCBI View Article : Google Scholar

7 

Zheng P, Liu F, Long J, Jin Y, Chen S, Duan G and Yang H: Latest advances in the application of humanized mouse model for Staphylococcus aureus. J Infect Dis. 228:800–809. 2023.PubMed/NCBI View Article : Google Scholar

8 

Deng J, Zhang BZ, Chu H, Wang XL, Wang Y, Gong HR, Li R, Yang D, Li C, Dou Y, et al: Adenosine synthase a contributes to recurrent Staphylococcus aureus infection by dampening protective immunity. EBioMedicine. 70(103505)2021.PubMed/NCBI View Article : Google Scholar

9 

Li J, Liu D, Tian X, Koseki S, Chen S, Ye X and Ding T: Novel antibacterial modalities against methicillin resistant Staphylococcus aureus derived from plants. Crit Rev Food Sci Nutr. 59 (Suppl 1):S153–S161. 2019.PubMed/NCBI View Article : Google Scholar

10 

Malczak I and Gajda A: Interactions of naturally occurring compounds with antimicrobials. J Pharm Anal. 13:1452–1470. 2023.PubMed/NCBI View Article : Google Scholar

11 

Wang L, Huang Y, Yin G, Wang J, Wang P, Chen ZY, Wang T and Ren G: Antimicrobial activities of Asian ginseng, American ginseng, and notoginseng. Phytother Res. 34:1226–1236. 2020.PubMed/NCBI View Article : Google Scholar

12 

Bostanghadiri N, Pormohammad A, Chirani AS, Pouriran R, Erfanimanesh S and Hashemi A: Comprehensive review on the antimicrobial potency of the plant polyphenol resveratrol. Biomed Pharmacother. 95:1588–1595. 2017.PubMed/NCBI View Article : Google Scholar

13 

Pastor RF, Restani P, Di Lorenzo C, Orgiu F, Teissedre PL, Stockley C, Ruf JC, Quini CI, Tejedor NG, Gargantini R, et al: Resveratrol, human health and winemaking perspectives. Crit Rev Food Sci Nutr. 59:1237–1255. 2019.PubMed/NCBI View Article : Google Scholar

14 

Zhang LX, Li CX, Kakar MU, Khan MS, Wu PF, Amir RM, Dai DF, Naveed M, Li QY, Saeed M, et al: Resveratrol (RV): A pharmacological review and call for further research. Biomed Pharmacother. 143(112164)2021.PubMed/NCBI View Article : Google Scholar

15 

Ignatowicz E and Baer-Dubowska W: Resveratrol, a natural chemopreventive agent against degenerative diseases. Pol J Pharmacol. 53:557–569. 2001.PubMed/NCBI

16 

Stervbo U, Vang O and Bonnesen C: A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem. 101:449–457. 2007.

17 

Cottart CH, Nivet-Antoine V, Laguillier-Morizot C and Beaudeux JL: Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 54:7–16. 2010.PubMed/NCBI View Article : Google Scholar

18 

Ma DSL, Tan LTH, Chan KG, Yap WH, Pusparajah P, Chuah LH, Ming LC, Khan TM, Lee LH and Goh BH: Resveratrol-potential antibacterial agent against foodborne pathogens. Front Pharmacol. 9(102)2018.PubMed/NCBI View Article : Google Scholar

19 

Özyalçın B and Sanlier N: Antiobesity pathways of pterostilbene and resveratrol: A comprehensive insight. Crit Rev Food Sci Nutr. 1–9. 2023.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).

20 

Abedini E, Khodadadi E, Zeinalzadeh E, Moaddab SR, Asgharzadeh M, Mehramouz B, Dao S and Samadi KH: A comprehensive study on the antimicrobial properties of resveratrol as an alternative therapy. Evid Based Complement Alternat Med. 2021(8866311)2021.PubMed/NCBI View Article : Google Scholar

21 

El-Mahdy AM, Alqahtani M, Almukainzi M, Alghoribi MF and Abdel-Rhman SH: Effect of resveratrol and curcumin on gene expression of methicillin-resistant Staphylococcus aureus (MRSA) toxins. J Microbiol Biotechnol. 34:141–148. 2024.PubMed/NCBI View Article : Google Scholar

22 

Oliveira AR, Domingues FC and Ferreira S: The influence of resveratrol adaptation on resistance to antibiotics, benzalkonium chloride, heat and acid stresses of Staphylococcus aureus and listeria monocytogenes. Food Control. 73:1420–1425. 2017.

23 

Paulo L, Ferreira S, Gallardo E, Queiroz JA and Domingues F: Antimicrobial activity and effects of resveratrol on human pathogenic bacteria. World J Microbiol Biotechnol. 26:1533–1538. 2010.

24 

Prevete G, Simonis B, Mazzonna M, Mariani F, Donati E, Sennato S, Ceccacci F and Bombelli C: Resveratrol and resveratrol-loaded galactosylated liposomes: Anti-adherence and cell wall damage effects on Staphylococcus aureus and MRSA. Biomolecules. 13(1494)2023.PubMed/NCBI View Article : Google Scholar

25 

Nøhr-Meldgaard K, Ovsepian A, Ingmer H and Vestergaard M: Resveratrol enhances the efficacy of aminoglycosides against Staphylococcus aureus. Int J Antimicrob Agents. 52:390–396. 2018.PubMed/NCBI View Article : Google Scholar

26 

Singh D, Mendonsa R, Koli M, Subramanian M and Nayak SK: Antibacterial activity of resveratrol structural analogues: A mechanistic evaluation of the structure-activity relationship. Toxicol Appl Pharmacol. 367:23–32. 2019.PubMed/NCBI View Article : Google Scholar

27 

Liu Y, Zhou J, Qu Y, Yang X, Shi G, Wang X, Hong Y, Drlica K and Zhao X: Resveratrol antagonizes antimicrobial lethality and stimulates recovery of bacterial mutants. PLoS One. 11(e0153023)2016.PubMed/NCBI View Article : Google Scholar

28 

Tegos G, Stermitz FR, Lomovskaya O and Lewis K: Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob Agents Chemother. 46:3133–3141. 2002.PubMed/NCBI View Article : Google Scholar

29 

Sun D, Hurdle JG, Lee R, Lee R, Cushman M and Pezzuto JM: Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead. ChemMedChem. 7:1541–1545. 2012.PubMed/NCBI View Article : Google Scholar

30 

Chan MMY: Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol. 63:99–104. 2002.PubMed/NCBI View Article : Google Scholar

31 

Jung CM, Heinze TM, Schnackenberg LK, Mullis LB, Elkins SA, Elkins CA, Steele RS and Sutherland JB: Interaction of dietary resveratrol with animal-associated bacteria. FEMS Microbiol Lett. 297:266–273. 2009.PubMed/NCBI View Article : Google Scholar

32 

Zakova T, Rondevaldova J, Bernardos A, Landa P and Kokoska L: The relationship between structure and in vitro antistaphylococcal effect of plant-derived stilbenes. Acta Microbiol Immunol Hung. 65:467–476. 2018.PubMed/NCBI View Article : Google Scholar

33 

Skroza D, Šimat V, Smole Možina S, Katalinić V, Boban N and Generalić Mekinić I: Interactions of resveratrol with other phenolics and activity against food-borne pathogens. Food Sci Nutr. 7:2312–2318. 2019.PubMed/NCBI View Article : Google Scholar

34 

Qin N, Tan X, Jiao Y, Liu L, Zhao W, Yang S and Jia A: RNA-Seq-based transcriptome analysis of methicillin-resistant Staphylococcus aureus biofilm inhibition by ursolic acid and resveratrol. Sci Rep. 4(5467)2014.PubMed/NCBI View Article : Google Scholar

35 

Su Y, Ma L, Wen Y, Wang H and Zhang S: Studies of the in vitro antibacterial activities of several polyphenols against clinical isolates of methicillin-resistant Staphylococcus aureus. Molecules. 19:12630–12639. 2014.PubMed/NCBI View Article : Google Scholar

36 

Duan J, Li M, Hao Z, Shen X, Liu L, Jin Y, Wang S, Guo Y, Yang L, Wang L and Yu F: Subinhibitory concentrations of resveratrol reduce alpha-hemolysin production in Staphylococcus aureus isolates by downregulating saeRS. Emerg Microbes Infect. 7(136)2018.PubMed/NCBI View Article : Google Scholar

37 

Morán A, Gutierrez S, Martinez-Blanco H, Ferrero MA, Monteagudo-Mera A and Rodriguez-Aparicio LB: Non-toxic plant metabolites regulate staphylococcus viability and biofilm formation: A natural therapeutic strategy useful in the treatment and prevention of skin infections. Biofouling. 30:1175–1182. 2014.PubMed/NCBI View Article : Google Scholar

38 

Tang F, Li L, Meng XM, Li B, Wang CQ, Wang SQ, Wang TL and Tian YM: Inhibition of alpha-hemolysin expression by resveratrol attenuates Staphylococcus aureus virulence. Microb Pathog. 127:85–90. 2019.PubMed/NCBI View Article : Google Scholar

39 

Rasko DA and Sperandio V: Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 9:117–128. 2010.PubMed/NCBI View Article : Google Scholar

40 

Cheung GYC and Otto M: Virulence mechanisms of staphylococcal animal pathogens. Int J Mol Sci. 24(14587)2023.PubMed/NCBI View Article : Google Scholar

41 

Vestergaard M and Ingmer H: Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents. 53:716–723. 2019.PubMed/NCBI View Article : Google Scholar

42 

Gordon RJ and Lowy FD: Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 46 (Suppl 5):S350–S359. 2008.PubMed/NCBI View Article : Google Scholar

43 

Karygianni L, Ren Z, Koo H and Thurnheer T: Biofilm matrixome: Extracellular components in structured microbial communities. Trends Microbiol. 28:668–681. 2020.PubMed/NCBI View Article : Google Scholar

44 

Singh S, Singh SK, Chowdhury I and Singh R: Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents. Open Microbiol J. 11:53–62. 2017.PubMed/NCBI View Article : Google Scholar

45 

Vivero-Lopez M, Pereira-Da-Mota AF, Carracedo G, Huete-Toral F, Parga A, Otero A, Concheiro A and Alvarez-Lorenzo C: Phosphorylcholine-based contact lenses for sustained release of resveratrol: Design, antioxidant and antimicrobial performances, and in vivo behavior. ACS Appl Mater Interfaces. 14:55431–55446. 2022.PubMed/NCBI View Article : Google Scholar

46 

Vivero-Lopez M, Muras A, Silva D, Serro AP, Otero A, Concheiro A and Alvarez-Lorenzo C: Resveratrol-loaded hydrogel contact lenses with antioxidant and antibiofilm performance. Pharmaceutics. 13(532)2021.PubMed/NCBI View Article : Google Scholar

47 

Cho HS, Lee JH, Cho MH and Lee J: Red wines and flavonoids diminish Staphylococcus aureus virulence with anti-biofilm and anti-hemolytic activities. Biofouling. 31:1–11. 2015.PubMed/NCBI View Article : Google Scholar

48 

Lee K, Lee JH, Ryu SY, Cho MH and Lee J: Stilbenes reduce Staphylococcus aureus hemolysis, biofilm formation, and virulence. Foodborne Pathog Dis. 11:710–717. 2014.PubMed/NCBI View Article : Google Scholar

49 

Miller MB and Bassler BL: Quorum sensing in bacteria. Annu Rev Microbiol. 55:165–199. 2001.PubMed/NCBI View Article : Google Scholar

50 

Santos CA, Lima EMF, Franco BDGM and Pinto UM: Exploring phenolic compounds as quorum sensing inhibitors in foodborne bacteria. Front Microbiol. 12(735931)2021.PubMed/NCBI View Article : Google Scholar

51 

Fatima M, Amin A, Alharbi M, Ishtiaq S, Sajjad W, Ahmad F, Ahmad S, Hanif F, Faheem M and Khalil AAH: Quorum quenchers from reynoutria japonica in the battle against methicillin-resistant Staphylococcus aureus (MRSA). Molecules. 28(2635)2023.PubMed/NCBI View Article : Google Scholar

52 

Ji G, Beavis R and Novick RP: Bacterial interference caused by autoinducing peptide variants. Science. 276:2027–2030. 1997.PubMed/NCBI View Article : Google Scholar

53 

Wang B and Muir TW: Regulation of virulence in Staphylococcus aureus: Molecular mechanisms and remaining puzzles. Cell Chem Biol. 23:214–224. 2016.PubMed/NCBI View Article : Google Scholar

54 

Zhang Y, Ma N, Tan P and Ma X: Quorum sensing mediates gut bacterial communication and host-microbiota interaction. Crit Rev Food Sci Nutr. 64:3751–3763. 2024.PubMed/NCBI View Article : Google Scholar

55 

Paulander W, Varming AN, Bojer MS, Friberg C, Bæk K and Ingmer H: The agr quorum sensing system in Staphylococcus aureus cells mediates death of sub-population. BMC Res Notes. 11(503)2018.PubMed/NCBI View Article : Google Scholar

56 

Kong C, Neoh HM and Nathan S: Targeting Staphylococcus aureus toxins: A potential form of anti-virulence therapy. Toxins (Basel). 8(72)2016.PubMed/NCBI View Article : Google Scholar

57 

Berube BJ and Bubeck Wardenburg J: Staphylococcus aureus α-toxin: Nearly a century of intrigue. Toxins (Basel). 5:1140–1166. 2013.PubMed/NCBI View Article : Google Scholar

58 

Singh V and Phukan UJ: Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity. Med Microbiol Immunol. 208:585–607. 2019.PubMed/NCBI View Article : Google Scholar

59 

Alqahtani M, Almukainzi M, Alghoribi MF and El-Mahdy AM: Antivirulence effects of trans-resveratrol and curcumin on methicillin-resistant Staphylococcus aureus (MRSA) from Saudi Arabia. Life (Basel). 14(491)2024.PubMed/NCBI View Article : Google Scholar

60 

Ika IM, Vincken JP, van Dinteren S, Ter Beest E, Pos KM and Araya-Cloutier C: Prenylated isoflavonoids from Fabaceae against the NorA efflux pump in Staphylococcus aureus. Sci Rep. 13(22548)2023.PubMed/NCBI View Article : Google Scholar

61 

Jang S: Multidrug efflux pumps in Staphylococcus aureus and their clinical implications. J Microbiol. 54:1–8. 2016.PubMed/NCBI View Article : Google Scholar

62 

Schindler BD, Jacinto P and Kaatz GW: Inhibition of drug efflux pumps in Staphylococcus aureus: Current status of potentiating existing antibiotics. Future Microbiol. 8:491–507. 2013.PubMed/NCBI View Article : Google Scholar

63 

Liu L, Ingmer H and Vestergaard M: Genome-wide identification of resveratrol intrinsic resistance determinants in Staphylococcus aureus. Antibiotics (Basel). 10(82)2021.PubMed/NCBI View Article : Google Scholar

64 

Liu L, Beck C, Nøhr-Meldgaard K, Peschel A, Kretschmer D, Ingmer H and Vestergaard M: Inhibition of the atp synthase sensitizes Staphylococcus aureus towards human antimicrobial peptides. Sci Rep. 10(11391)2020.PubMed/NCBI View Article : Google Scholar

65 

Vestergaard M, Nøhr-Meldgaard K, Bojer MS, Krogsgård Nielsen C, Meyer RL, Slavetinsky C, Peschel A and Ingmer H: Inhibition of the ATP synthase eliminates the intrinsic resistance of Staphylococcus aureus towards polymyxins. mBio. 8:e01114–17. 2017.PubMed/NCBI View Article : Google Scholar

66 

Vestergaard M, Roshanak S and Ingmer H: Targeting the ATP synthase in Staphylococcus aureus small colony variants, streptococcus pyogenes and pathogenic fungi. Antibiotics (Basel). 10(376)2021.PubMed/NCBI View Article : Google Scholar

67 

Alshehri FS: Resveratrol ameliorates vancomycin-induced testicular dysfunction in male rats. Medicina (Kaunas). 59(486)2023.PubMed/NCBI View Article : Google Scholar

68 

Tosato MG, Schilardi PL, de Mele MFL, Thomas AH, Miñán A and Lorente C: Resveratrol enhancement Staphylococcus aureus survival under levofloxacin and photodynamic treatments. Int J Antimicrob Agents. 51:255–259. 2018.PubMed/NCBI View Article : Google Scholar

69 

Dwyer DJ, Collins JJ and Walker GC: Unraveling the physiological complexities of antibiotic lethality. Annu Rev Pharmacol Toxicol. 55:313–332. 2015.PubMed/NCBI View Article : Google Scholar

70 

Dos Santos DP, Galantini MPL, Ribeiro IS, Muniz IPR, Pereira IS and da Silva RAA: Photoactivated resveratrol controls intradermal infection by Staphylococcus aureus in mice: A pilot study. Lasers Med Sci. 35:1341–1347. 2020.PubMed/NCBI View Article : Google Scholar

71 

Dos Santos DP, Soares Lopes DP, de Moraes RC Jr, Vieira Gonçalves C, Pereira Rosa L, da Silva Rosa FC and da Silva RAA: Photoactivated resveratrol against Staphylococcus aureus infection in mice. Photodiagnosis Photodyn Ther. 25:227–236. 2019.PubMed/NCBI View Article : Google Scholar

72 

Lee IT, Lin CC, Yang CC, Hsiao LD, Wu MY and Yang CM: Resveratrol attenuates Staphylococcus aureus-induced monocyte adhesion through downregulating PDGFR/AP-1 activation in human lung epithelial cells. Int J Mol Sci. 19(3058)2018.PubMed/NCBI View Article : Google Scholar

73 

Shevelev AB, La Porta N, Isakova EP, Martens S, Biryukova YK, Belous AS, Sivokhin DA, Trubnikova EV, Zylkova MV, Belyakova AV, et al: In vivo antimicrobial and wound-healing activity of resveratrol, dihydroquercetin, and dihydromyricetin against Staphylococcus aureus, pseudomonas aeruginosa, and candida albicans. Pathogens. 9(296)2020.PubMed/NCBI View Article : Google Scholar

74 

Wu S and Huang J: Resveratrol alleviates Staphylococcus aureus pneumonia by inhibition of the NLRP3 inflammasome. Exp Ther Med. 14:6099–6104. 2017.PubMed/NCBI View Article : Google Scholar

75 

Joseph A, Balakrishnan A, Shanmughan P, Maliakel B and Illathu Madhavamenon K: Micelle/hydrogel composite as a ‘natural self-emulsifying reversible hybrid hydrogel (N'SERH)’ enhances the oral bioavailability of free (unconjugated) resveratrol. ACS Omega. 7:12835–12845. 2022.PubMed/NCBI View Article : Google Scholar

76 

Walle T: Bioavailability of resveratrol. Ann N Y Acad Sci. 1215:9–15. 2011.PubMed/NCBI View Article : Google Scholar

77 

Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 16:1246–1252. 2007.PubMed/NCBI View Article : Google Scholar

78 

Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, et al: Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 70:9003–9011. 2010.PubMed/NCBI View Article : Google Scholar

79 

Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C and Redfield R: Resveratrol glucuronides as the metabolites of resveratrol in humans: Characterization, synthesis, and anti-HIV activity. J Pharm Sci. 93:2448–2457. 2004.PubMed/NCBI View Article : Google Scholar

80 

Walle T, Hsieh F, DeLegge MH, Oatis JE Jr and Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 32:1377–1382. 2004.PubMed/NCBI View Article : Google Scholar

81 

Tsugami Y, Nii T and Isobe N: Effects of topical application of resveratrol on tight junction barrier and antimicrobial compound production in lactating goat mammary glands. Vet Res. 55(20)2024.PubMed/NCBI View Article : Google Scholar

82 

Cottart CH, Nivet-Antoine V and Beaudeux JL: Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 58:7–21. 2014.PubMed/NCBI View Article : Google Scholar

83 

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R and Aisen PS: Alzheimer's Disease Cooperative Study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 85:1383–1391. 2015.PubMed/NCBI View Article : Google Scholar

84 

Shaito A, Posadino AM, Younes N, Hasan H, Halabi S, Alhababi D, Al-Mohannadi A, Abdel-Rahman WM, Eid AH, Nasrallah GK and Pintus G: Potential adverse effects of resveratrol: A literature review. Int J Mol Sci. 21(2084)2020.PubMed/NCBI View Article : Google Scholar

85 

Brown K, Theofanous D, Britton RG, Aburido G, Pepper C, Sri Undru S and Howells L: Resveratrol for the management of human health: How far have we come? A systematic review of resveratrol clinical trials to highlight gaps and opportunities. Int J Mol Sci. 25(747)2024.PubMed/NCBI View Article : Google Scholar

86 

Yadegar S, Mohammadi F, Yadegar A, Mohammadi Naeini A, Ayati A, Milan N, Tayebi A, Seyedi SA, Nabipoorashrafi SA, Rabizadeh S, et al: Effects and safety of resveratrol supplementation in older adults: A comprehensive systematic review. Phytother Res. 38:2448–2461. 2024.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

November-December 2024
Volume 4 Issue 6

Print ISSN: 2754-3242
Online ISSN:2754-1304

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cui W, Wang Y, Zhang L, Liu F, Duan G, Chen S, Long J, Jin Y and Yang H: Recent advances in the use of resveratrol against Staphylococcus aureus infections (Review). Med Int 4: 67, 2024.
APA
Cui, W., Wang, Y., Zhang, L., Liu, F., Duan, G., Chen, S. ... Yang, H. (2024). Recent advances in the use of resveratrol against Staphylococcus aureus infections (Review). Medicine International, 4, 67. https://doi.org/10.3892/mi.2024.191
MLA
Cui, W., Wang, Y., Zhang, L., Liu, F., Duan, G., Chen, S., Long, J., Jin, Y., Yang, H."Recent advances in the use of resveratrol against Staphylococcus aureus infections (Review)". Medicine International 4.6 (2024): 67.
Chicago
Cui, W., Wang, Y., Zhang, L., Liu, F., Duan, G., Chen, S., Long, J., Jin, Y., Yang, H."Recent advances in the use of resveratrol against Staphylococcus aureus infections (Review)". Medicine International 4, no. 6 (2024): 67. https://doi.org/10.3892/mi.2024.191